Large Cap Biopharmaceuticals Performance
Image Source: Unsplash
Large Cap Biopharmaceuticals-Performance Metrics
We provide this data on a quarterly basis to help investors with portfolio management of healthcare stocks. We see these large cap stocks as the best overall opportunity for investors within the healthcare sector. We gave a general overview of various subsectors last week as kind of oadmap of the components.But large caps provide top line growth with good value with dividends. But this strategy does require that the investor track news and earnings. As you can see from this data there is a lot of variability of performance over a 12 month period. Our top picks over the past 6 months has been: ABBV, LLY, MRK, REGN and VRTX. As a recent contrarian pick we believe that Pfizer (PFE) performance should turn around due to some recent pipeline deals particularly the acquisition of Seagen (SGEN) for it line of cancer therapies.
As a defensive play healthcare is weighted at about 12% of the S&P 500 not so big considering that Technology stocks (XLK) are weighted at about 29.86% and have gained 2% YTD and about 31 % over one year. The recent applications of AI tools and importance of data management have driven technology and semiconductor stocks to new highs.
Here are some takeaways from this data:
- The top performing stocks YTD and the past 12 months are: ABBV, LLY, AMGN, MRK, VRTX, and REGN.
- The laggards are: BMY, BIIB, GILD, and PFE.
- M&A has been a major factor for building product pipeline, core technology and top line growth examples include ABBV, AZN, GILD, and MRK.
- Keep in mind that JNJ has got through a major restructuring with spinoff of Kenvue and is now focused on Biopharma and Medtech.
- There is not an ETF for investing in these stocks but you can get some play with diversification with one ETF(XLV) and ONE Fund (PRHSX).
- The major products event has been the GLP-1 class of weight loss drugs by Lilly and Novo Nordisk.
- The biotech sector remains a laggard YTD as can be seen by the IBB.
- Drug pricing remains a target for Congress with expectations for the IRA Medicare drug pricing legislation to hit selected companies in September.
LONG: ABBV, AZN, GILD, LLY, MRK, PFE, REGN, VRTX.
| 1/15/18 | 3/31/23 | 11/1/19 | 10/8/2023 | 2024 | YTD | FWD | Analyst | % | 52 week H | 1 yr % | monthly | |||||
| Company | Ticker | Price | Price | Price | Price | PRICE | % Perf | tech | ||||||||
| 5/19/24 | % Perf | P/S | PE | Recom | Div | |||||||||||
| Abbvie | ABBV | 100.000 | 159.37 | 81.75 | 148.23 | 166.42 | 7.39 | 5.66 | 13.82 | 1.97 | 3.75 | 183 | 16.09 | u | ||
| Alexion*(ALXN) | ALXN | 123.000 | 182.5 | 109.38 | – | 40.33 | n/a | 4.56 | 9.38 | n/a | *acquired by AZN | AZN | ||||
| Amgen | AMGN | 185.000 | 241.75 | 221 | 263 | 312.47 | 8.49 | 5.71 | 15.11 | 2.17 | 2.97 | 329 | 38.86 | u | ||
| AstraZeneca* | AZN | 35.000 | 69.41 | 40.34 | 67.42 | 76.9 | 14.18 | 5.01 | 16.38 | 1.66 | 1.89 | 77.93 | 2.95 | u | ||
| Biogen | BIIB | 336.000 | 278.31 | 299.2 | 263.25 | 230.57 | -10.9 | 3.62 | 13.21 | 1.62 | – | 276.52 | -24.71 | u | ||
| Bristol Myers* | BMY | 63.000 | 69.31 | 57.16 | 56.66 | 44.03 | -14.19 | 1.96 | 6.34 | 2.64 | 5.47 | 67.06 | -33.82 | d | ||
| Celgene* (BMY) | CELG | 106.000 | n/a | 108.53 | – | 77 | n/a | 4.69 | 8.7 | n/a |
*acquired by BMY |
|||||
| Gilead Sci | GILD | 79.000 | 82.97 | 61.69 | 74.74 | 67.72 | -16.41 | 3.08 | 9.47 | 2.18 | 4.62 | 87.87 | -14.07 | d | ||
| GlaxoSmithK* | GSK | 38.000 | 35.58 | 45 | 36.65 | 44.98 | 21.37 | 2.37 | 10.11 | 2.36 | 3.39 | 45.93 | 24.46 | u | ||
| Johnson&J* | JNJ | new | 154.64 | -1.34 | 4.15 | 14.11 | 2.17 | 3.11 | 175.97 | -2.74 | – | |||||
| Eli Lilly | LLY | 85.000 | 343.42 | 113 | 565.22 | 770 | 32.09 | 20.37 | 40.25 | 0.6 | 0.71 | 800.78 | 76 | u- | ||
| Merck | MRK | 59.000 | 106.39 | 78 | 103.88 | 131.9 | 20.34 | 5.44 | 13.2 | 1.52 | 2.41 | 133.1 | 17.55 | u | ||
| Pfizer | PFE | 40.8 | 33.13 | 28.64 | -0.52 | 2.95 | 10.52 | 2.22 | 5.9 | 40.37 | -22.07 | u | ||||
| Regeneron | REGN | 367.000 | 821.67 | 310.48 | 836.57 | 982.29 | 11.84 | 7.98 | 20.17 | 1.76 | – | 998.33 | 31.04 | u | ||
| Vertex | VRTX | 158.000 | 315.07 | 196 | 360.62 | 445.21 | 9.42 | 11.29 | 24.36 | 1.94 | – | 422.91 | 31.04 | u | ||
| 3/31 | 11/19 | 10/7/23 | 5/19/24 |
%YTD |
||||||||||||
| XBI | 76.21 | 93 | 72.23 | 91.18 | 2.12 | 103.52 | 0.34 | u | ||||||||
| IBB | 129.16 | 119.65 | 122.48 | 136.69 | 0.62 | 141.16 | 5.69 | u/- | ||||||||
| FBIOX | 15.63 | 20.26 | 15.47 | 18.7 | 3.87 | 18.7 | 9.98 | u | ||||||||
| PRHSX | 87.75 | 79 | 86.37 | 93.4 | 6.26 | 95.49 | 2.6 | u/- | ||||||||
| XLV | 129.46 | 121.11 | 1 | 146.31 | 7.28 | 148.27 | 11.67 | u | ||||||||
| XPH | 41.01 | 39.47 | 39.05 | 41.17 | -1.08 | 45.62 | 1.03 | d | ||||||||
| UNH | 472.59 | 252 | 524.81 | 524.63 | -0.35 | 545.62 | 8.21 | u | ||||||||
| QQQ | 320.93 | 201.23 | 364.7 | 451.75 | 10.31 | 454.75 | 36.43 | u | ||||||||
More By This Author:
Healthcare And Biotech Investing 101: What You Need To Know.
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Healthcare And Biotech Stocks Review: Q1 2024 Performance
Comments
